Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2003

01-10-2003

A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine

Authors: Judith Clancy Keen, Lan Yan, Kelly M. Mack, Catherine Pettit, Dawn Smith, Dipali Sharma, Nancy E. Davidson

Published in: Breast Cancer Research and Treatment | Issue 3/2003

Login to get access
Metadata
Title
A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine
Authors
Judith Clancy Keen
Lan Yan
Kelly M. Mack
Catherine Pettit
Dawn Smith
Dipali Sharma
Nancy E. Davidson
Publication date
01-10-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1026146524737

Other articles of this Issue 3/2003

Breast Cancer Research and Treatment 3/2003 Go to the issue

Instructions for Authors

Instructions for Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine